DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 02 · Volume 25 · March 1992 DOI: 10.1055/s-002-10089

Preface

  • 63
    Maitre, L.:

    17th Symposium of AGNP, Nuremberg 1991

  • 64
    Müller-Spahn, F.; Oswald, W. D.; Heuser, I.; Hoyer, S.; Leenders, K. L.; Stoppe, G.:

    Dementia - New Aspects in Early Diagnosis

  • 65
    Schlegel, S.:

    Receptor Mapping by Single Photon Emission Computerized Tomography in Relation to Clinical Aspects and Pharmacopsychiatry

  • 66
    Strauss, W. H.; Klieser, E.:

    Combination of Pharmacotherapy and Psychotherapy/Advantage or Disadvantage

  • 67
    Linden, M.:

    Epidemiological Methods in the Evaluation of Drugs, Field Studies in the Postmarketing Phase

  • 68
    Steiger, A.:

    Ligands of the GABA-Benzodiazepine-Receptor-Complex - Recent Clinical and Neurobiological Research

  • 69
    Kissling, W.; Fleischhacker, W. W.:

    Optimising Prophylactic Treatment of Schizophrenia by Means of Treatment Standards and Compliance Improvement

  • 71
    Gaebel, W.; Ellgring, H.:

    Experimental Psychopathology in Biological Psychiatry and Psychopharmacology

  • 72
    Hiemke, C.:

    Drug Monitoring in Psychiatric Patients:Which Approach is Userul to ImprovePsychopharmacotherapy?

  • 74
    Fleischhacker, W. W.:

    Clozapine - Beneficial and Untoward Effects: An Update

  • 75
    Möller, H. J.; Helmchen, H.:

    Organisatory and Ethical Aspects of Clinical Trials

  • 76
    Albus, M.; Netter, P.:

    Methodological Aspects of Studies with Anxiolytics

  • 77
    Krüger, H. P.:

    Speech Chronemics in Drug Evaluation